Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study.

Conclusions: There was an increase in survival among men with de novo metastatic prostate cancer in Sweden between 1998 and 2015. This increase was due to a decreased cancer extent indicated by lower PSA levels with ensuing longer lead times and speculatively also due to an increased use of chemotherapy in the latest time period. Given the increasing use of systemic treatment for advanced prostate cancer, our results are likely heralding larger increases in survival in men with metastatic prostate cancer in the near future. PMID: 31526166 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31526166?dopt=Abstract

Source: Acta Oncologica - September 16, 2019 Category: Cancer & Oncology Authors: Westerberg M, Franck Lissbrant I, Damber JE, Robinson D, Garmo H, Stattin P Tags: Acta Oncol Source Type: research